Gene interactions and pathways from curated databases and text-mining
J Neurooncol 2010, PMID: 19562254

Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.

Reardon, David A; Desjardins, Annick; Vredenburgh, James J; Gururangan, Sridharan; Friedman, Allan H; Herndon, James E; Marcello, Jennifer; Norfleet, Julie A; McLendon, Roger E; Sampson, John H; Friedman, Henry S

We evaluated the anti-tumor activity and safety of erlotinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor, plus sirolimus, an inhibitor of the mammalian target of rapamycin, among patients with recurrent glioblastoma (GBM) in a phase 2, open-label, single-arm trial. Thirty-two patients received daily erlotinib and sirolimus. The doses of erlotinib and sirolimus were 150 mg and 5 mg for patients not on concurrent CYP3A-inducing anti-epileptics (EIAEDS), and 450 mg and 10 mg for patients on EIAEDS. Evaluations were performed every two months. The primary endpoint was 6-month progression-free survival and secondary endpoints included safety and overall survival. Archival tumor samples were assessed for EGFR, EGFRvIII, PTEN, pAKT and pS6. Enrolled patients were heavily pre-treated including 53% who had received three or more prior chemotherapy agents and 28% who had received prior bevacizumab therapy. The most common grade > or = 2 adverse events were rash (59%), mucositis (34%) and diarrhea (31%). Grade 3 or higher events were rare. Best radiographic response included stable disease in 15 patients (47%); no patients achieved either a CR or PR. The estimated 6-month progression-free survival was 3.1% for all patients. Progression-free survival was better for patients not on EIAEDs (P = 0.03). Tumor markers failed to show an association with PFS except for increased pAKT expression which achieved borderline significance (P = 0.045). Although neither rash nor diarrhea had an association with outcome, hyperlipidemia was associated with longer PFS (P = 0.029). Erlotinib plus sirolimus was well tolerated but had negligible activity among unselected recurrent GBM patients. (ClinicalTrials.gov number: NCT0062243).

Diseases/Pathways annotated by Medline MESH: Central Nervous System Neoplasms, Glioblastoma, Neoplasm Recurrence, Local
Document information provided by NCBI PubMed

Text Mining Data

mammalian target of rapamycin → epidermal growth factor receptor: " We evaluated the anti-tumor activity and safety of erlotinib, a receptor tyrosine kinase inhibitor of the epidermal growth factor receptor , plus sirolimus, an inhibitor of the mammalian target of rapamycin , among patients with recurrent glioblastoma ( GBM ) in a phase 2, open-label, single-arm trial "

Manually curated Databases

No curated data.